Core Viewpoint - The company reported a significant increase in revenue and profit for the mid-term of 2025, driven by its healthcare solutions business, and announced a share buyback plan [1] Financial Performance - Revenue for the mid-term of 2025 reached 1.495 billion RMB, representing a year-on-year increase of 9.52% [1] - EBITDA was approximately 270 million RMB, showing a year-on-year growth of 37.3% [1] - Shareholder profit attributable to the company was 152 million RMB, an increase of 41.9% compared to the previous year [1] - The company proposed an interim dividend of 0.35 HKD per share, up from 0.13 HKD in the same period last year [1] Share Buyback Plan - The company’s board has resolved to exercise a buyback authorization, planning to repurchase shares in the open market for a total price of up to 300 million HKD [1] - The company intends to use its internal resources for the buyback [1] - Under the buyback authorization, the board can repurchase up to 23.6965 million shares, which accounts for 10% of the total issued shares as of June 20, 2025 [1]
固生堂涨近4% 上半年纯利同比增四成 拟斥最多3亿港元适时回购股份